The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

• Authors: MALČÍKOVÁ Jitka; RÁZGA Filip; JURČEK Tomáš; DVOŘÁKOVÁ Dana; ŽÁČKOVÁ Daniela; TOŠKOVÁ Hana; ŠEBEJOVÁ Ludmila; ŠMARDOVÁ Jana; OLTOVÁ Alexandra; VAŇKOVÁ Gabriela; JURAČKOVÁ Lenka; TRBUŠEK Martin; POSPÍŠILOVÁ Šárka; MAYER Jiří; RÁČIL Zdeněk
• Year of publication: 2013
• Type: Article in Periodical
• Magazine / Source: Leukemia & Lymphoma
• MU Faculty or unit: Central European Institute of Technology
• web: http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal
• Doi: http://dx.doi.org/10.3109/10428194.2012.762649
• Field: Oncology and hematology
• Keywords: BCR-ABL1; T315I; chronic myelogenous leukemia; therapy

Attached files

• EL_1163539_The_BCR-ABL1.pdf

• Description: The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.